Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation?

Global gene expression profiling studies have classified breast cancer into molecular classes, some of which show similarity to normal mammary cells (ie luminal and basal subtypes) with a subsequent histogenetic implication that reinforced the perception that the phenotype of breast cancer reflects the cell of origin. However, it remains to be determined whether phenotypic changes are the result of malignant transformation of particular cancer stem cells (histogenesis) or specific genetic hits occurring at various stages of carcinogenesis (dedifferentiation). We sought to test the hypothesis that dedifferentiation may be the more likely explanation using in vivo clinical data. Our findings support the hypothesis that at least some metaplastic carcinomas are derived from phenotypic transition from conventional mammary adenocarcinoma either at the in‐situ, primary invasive stage or at a distant metastatic site. This observation argues against the cell of origin theory (histogenesis) for breast carcinogenesis and favours the concept of tumour dedifferentiation at later stages. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  Pieter Wesseling,et al.  Receptor conversion in distant breast cancer metastases , 2010, Breast Cancer Research.

[2]  A. Ashworth,et al.  BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. , 2010, Cell stem cell.

[3]  A. Ashworth,et al.  Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas , 2010, The Journal of pathology.

[4]  F. Akiyama,et al.  Histogenesis of metaplastic breast carcinoma and axillary nodal metastases , 2009, Pathology international.

[5]  B. Kreike,et al.  Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis , 2009, Breast Cancer Research and Treatment.

[6]  C. Reynolds,et al.  Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy , 2008, Molecular Cancer Therapeutics.

[7]  S. Lakhani,et al.  Metaplastic breast carcinomas are basal‐like tumours , 2006, Histopathology.

[8]  S. Schnitt,et al.  Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer , 2006, Modern Pathology.

[9]  P. Tan,et al.  Metaplastic carcinoma of the breast: a clinicopathological review , 2006, Journal of Clinical Pathology.

[10]  Chiun-Sheng Huang,et al.  p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components , 2004, The Journal of pathology.

[11]  J. Thiery Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[12]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[14]  S. Love,et al.  ‘Revertant’ DCIS in human axillary breast carcinoma metastases , 1997, The Journal of pathology.

[15]  H M Jensen,et al.  An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. , 1975, Journal of the National Cancer Institute.

[16]  H M Jensen,et al.  On the origin and progression of ductal carcinoma in the human breast. , 1973, Journal of the National Cancer Institute.